INTRODUCTION: @entity320 of the head and neck is a @entity395 with limited data available on outcomes; therefore, we reviewed our institutional experience. METHODS: An institutional database was queried and 38 @entity1 with head and neck @entity320 were identified. Charts were abstracted and local control (LC), progression-free survival (PFS) and @entity1349 ( @entity1349 ) were calculated. RESULTS: Most @entity1 had @entity66 (86%), although nodes were positive in 11%. En bloc or endoscopic resection was performed on 93%. Adjuvant or definitive radiotherapy to a median dose of 60   Gy was utilized in 90%. Chemotherapy was given in 21%, and 16% received interferon. Three-year LC, PFS and @entity1349 were 90%, 48% and 59%, respectively. Median @entity1349 was 4.6 years. Site of first failure was distant in 52% of cases. CONCLUSION: With aggressive therapy median @entity1349 was 4.6 years in this cohort. Distant recurrence remains the primary mode of failure. It may be reasonable to include @entity320 @entity1 in trials of systemic agents along with high-risk cutaneous @entity320 .

Outcomes of XXXX of the head and neck.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['T4 disease'] @entity395 :: ('MESH:D035583', 'Disease') :: ['rare disease'] @entity320 :: ('MESH:D008545', 'Disease') :: ['Mucosal melanoma', 'melanomas', 'mucosal melanoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity320 :: (MESH:D008545,Disease) :: ['mucosal melanoma']
